Experimental cutaneous Leishmaniasis: Induction and regulation of T cells following infection of mice with Leishmania major

Chemical Immunology

Volumn 70, Issue , 1998, Pages 60-80

  Scott, Phillip ^a   Farrell, Jay P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARASITIC AGENT; CD4 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 4; MONOCLONAL ANTIBODY; STIBOGLUCONATE SODIUM; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; CELLULAR IMMUNITY; DISEASE PREDISPOSITION; HELPER CELL; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; INFECTION CONTROL; KNOCKOUT MOUSE; LEISHMANIA MAJOR; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MACROPHAGE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN LEISHMANIASIS; T LYMPHOCYTE ACTIVATION;

ANIMALS; CELL DIFFERENTIATION; CYTOKINES; IMMUNITY, CELLULAR; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, KNOCKOUT; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES;

EID: 0031963998     PISSN: 10150145     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Liew FY, O'Donnell CA: Immunology of leishmaniasis. Adv Parasitol 1993;32:162-259.
2. Bogdan C, Gessner A, Rollinghoff M: Cytokines in leishmaniasis: A complex network of stimulatory and inhibitory interactions. Immunobiology 1993;189:356-396.
3. Reiner SL, Locksley RM: The regulation of immunity to Leishmania major. Annu Rev Immunol 1995;13:151-177.
4. Turk JL, Bryceson ADM: Immunologic phenomena in leprosy and related diseases. Adv Immunol 1971;13:209-266.
5. Wyler DJ, Marsden PD: Leishmaniasis; in Warren KS, Mahmoud AAF (eds): Tropical and Geographical Medicine. New York, McGraw-Hill, 1984, pp 270-280.
6. Locksley RM, Scott P: Helper T-cell subsets in mouse leishmaniasis: Induction, expansion and effector function. Immunol Today 1991;12:A58-A61.
7. Scott P: Th cell development and regulation in experimental cutaneous leishmaniasis; in Romagnani S (ed): Th1 and Th2 Cells in Health and Disease. Chem Immunol. Basel, Karger, 1995, vol 63, pp 98-114.
8. Grimaldi G Jr, Moriearty PL, Hoff R: Leishmania mexicana: Immunology and histopathology in C3H mice. Exp Parasitol 1980;50:45-56.
9. Barral A, Petersen EA, Sacks DL, Neva FA: Late metastatic leishmaniasis in the mouse. A model for mucocutaneous disease. Am J Trop Med Hyg 1983;32:277-285.
10. Afonso LCC, Scott P: Immune responses associated with the susceptibility of C57BL/10 mice to Leishmania amazonensis. Infect Immun 1993;61:2952-2959.
11. Howard JG, Hale C, Liew FY: Immunologic regulation of experimental cutaneous leishmaniasis. IV. Prophylactic effect of sublethal irradiation as a result of abrogation of suppressor T cell generation in mice genetically susceptible to Leishmania tropica. J Exp Med 1981;153:557-568.
12. Locksley RM, Reiner SL, Hatam F, Littman DR, Killeen N: Helper T cells without CD4: Control of leishmaniasis in CD4-deficient mice. Science 1993;261:1448-1451.
13. Scott P, Natovitz P, Coffman RL, Pearce E, Sher A: Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J Exp Med 1988;168:1675-1684.
14. Heinzel FP, Sadick MD, Holaday BJ, Coffman RL, Locksley RM: Reciprocal expression of interferon-gamma or IL-4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J Exp Med 1989;169:59-72.
15. Scott P: IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis. J Immunol 1991;147:3149-3155.
16. Chatelain R, Varkila K, Coffman RL: IL-4 induces a Th2 response in Leishmania major-infected mice. J Immunol 1992;148:1182-1187.
17. Scharton-Kersten T, Afonso LCC, Wysocka M, Trinchieri G, Scott P: IL-2 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis. J Immunol 1995;154:5320-5330.
18. O'Garra A, Murphy K: Role of cytokines in determining T-lymphocyte function. Curr Opin Immunol 1994;6:458-466.
19. Scharton TM, Scott P: Natural killer cells are a source of IFN-γ that drives differentiation of CD4+ T cell subsets and induces early resistance to Leishmania major in mice. J Exp Med 1993;178:567-577.
20. Scharton-Kersten T, Scott P: The role of the innate immune response in Th1 cell development following Leishmania major infection. J Leukoc Biol 1995;57:515-522.
21. Heinzel FP, Rerko RM, Ahmed F, Pearlman E: Endogenous IL-12 is required for control of Th2 cytokine responses. J Immunol 1995;155:730-739.
22. Sypek JP, Chung CL, Mayor SEH, Subramanyam JM, Goldman SJ, Sieburth DS, Wolf SF, Schaub RG: Resolution of cutaneous leishmaniasis: Interleukin-12 initiates a protective Th1 immune response. J Exp Med 1993;177:1797-1802.
23. Afonso LCC, Scharton TM, Vieira LQ, Wysocka M, Trinchieri G, Scott P: The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 1994;263:235-237.
24. Sadick MD, Heinzel FP, Holaday BJ, Pu RT, Dawkins RS, Locksley RM: Cure of murine leishmaniasis with anti-interleukin-4 monoclonal antibody. Evidence for a T cell-dependent, interferon-gamma-independent mechanism. J Exp Med 1990;171:115-127.
25. Mattner F, Magram J, Ferrante J, Launois P, Di Padova K, Behin R, Gately MK, Louis JA, Alber G: Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur J Immunol 1996;26:1553-1559.
26. Reiner SL, Zheng S, Wang Z-E, Stowring L, Locksley RM: Leishmania promastigotes evade interleukin-12 induction by macrophages and stimulate a broad range of cytokines from CD4+ T cells during initiation of infection. J Exp Med 1994;179:447-456.
27. Vieira LQ, Hondowicz BD, Afonso LCC, Wysocka M, Trinchieri G, Scott P: Infection with Leishmania major induces interleukin-12 production in vivo. Immunol Letters 1994;40:157-161.
28. Skeiky YA, Guderian JA, Benson DR, Bacelar O, Carvalho EM, Kubin M, Badaro R, Trincheiri G, Reed SG: A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin-12. J Exp Med 1995; 181:1527-1537.
29. Campbell KA, Ovendale PJ, Kennedy MK, Fanslow WC, Reed SG, Maliszewski CR: CD40 ligand is required for protective cell-mediated immunity to Leishmania major. Immunity 1996;4:283-290.
30. Soong L, Su J-C, Grewal IS, Kima P, Sun J, Longley BJ, Ruddle NH, McMahon-Pratt D, Flavell RA: Disruption of CD40-CD40 ligand interactions results in enhanced susceptibility to Leishmania amazonensis infection. Immunity 1996;4:263-274.
31. Kamanaka M, Yu P, Yasui T, Yoshida K, Kawabe T, Horii T, Kishimoto T, Kikitana H: Protective role of CD40 in Leishmania major infection at two distinct phases of cell-mediated immunity. Immunity 1996;4:275-282.
32. -. Eur J Immunol 1996;25:3298-3307.
33. + T cells are not essential for T helper cell 2 immune responses. J Exp Med 1996;184:1295-1304.
34. Scott P, Caspar P, Sher A: Protection against Leishmania major in BALB/c mice by adoptive transfer of a T cell clone recognizing a low molecular weight antigen released by promastigotes. J Immunol 1990;144:1075-1079.
35. Mougneau E, Altare F, Wakil AE, Zheng S, Coppola T, Wang LE, Waldmann R, Locksley RM, Glaichenhaus N: Expression cloning of a protective Leishmania antigen. Science 1995;268:563-566.
36. Julia V, Rassoulzadegan M, Glaichenhaus N: Resistance to Leishmania major induced by tolerance to a single antigen. Science 1996;274:421-423.
37. Reiner SL, Wang Z-E, Hatam F, Scott P, Locksley RM: Common lineage of Th1 and Th2 subsets in leishmaniasis. Science 1993;259:1457-1460.
38. 1 mice infected with Leishmania major. Parasite Immunol 1995;17:569-579.
39. Scott P, Eaton A, Gause WC, Zhou XD, Hondowicz B: Early IL-4 production does not predict susceptibility to Leishmania major. Exp Parasitol 1996;84:178-187.
40. Guler ML, Gorham JD, Hsieh C-S, Mackey AJ, Steen RG, Dietrich WF, Murphy KM: Genetic susceptibility to Leishmania: IL-12 responsiveness in Th1 cell development. Science 1996;271:984-986.
41. Noben-Trauth N, Kropf P, Muller I: Susceptibility to Leishmania major infection in interleukin-4-deficient mice. Science 1996;271:987-990.
42. Kopf M, Brombacher F, Kohler G, Kienzle G, Widmann K-H, Lefrang K, Humborg C, Ledermann B, Solbach W: IL-4 deficient BALB/c mice resist infection with Leishmania major. J Exp Med 1996: 184;1127-1136.
43. Bretscher PA, Wei G, Menon JN, Bielefeldt-Ohmann H: Establishment of stable, cell-mediated immunity that makes 'susceptible' mice resistant to Leishmania major. Science 1992;257:539-542.
44. Nabors GS, Farrell JP: Site-specific immunity to Leishmania major in SWR mice: The site of infection influences susceptibility and expression of the antileishmanial immune response. Infect Immun 1994;62:3655-3662.
45. Mitchell GF, Curtis JM, Scollay RG, Handman E: Resistance and abrogation of resistance to cutaneous leishmaniasis in reconstituted BALB/c nude mice. Aust J Exp Med Biol Sci 1981;59: 539-554.
46. Varkila K, Chatelain R, Leal LMCC, Coffman RL: Reconstitution of C.B-17 SCID mice with BALB/c T cells initiates a T helper type-1 response and renders them capable of healing Leishmania major infection. Eur J Immunol 1993;23:262-268.
47. Titus RG, Ceredig R, Cerottini JC, Louis JA: Therapeutic effect of anti-L3T4 monoclonal antibody GK1.5 on cutaneous leishmaniasis in genetically-susceptible BALB/c mice. J Immunol 1985;135: 2108-2114.
48. Heinzel FP, Rerko RM, Hatam R, Locksley RM: IL-2 is necessary for the progression of leishmaniasis in susceptible murine hosts. J Immunol 1993;150:3924-3931.
49. Corry DB, Reiner SL, Linsley PS, Locksley RM: Differential effects of blockade of CD28-B7 on the development of Th1 or Th2 effector cells in experimental leishmaniasis. J Immunol 1994;153: 4142-4148.
50. Brown DR, Green JM, Moskowitz NH, Davis M, Thompson CB, Reiner SL: Limited role of CD28-mediated signals in T helper subset differentiation. J Exp Med 1996;184:803-810.
51. Kundig TM, Shahinian A, Kawai K, Mittrucker H-W, Sebzda E, Bachmann MF, Mak TW, Ohashi PS: Duration of TCR stimulation determines costimulatory requirement of T cells. Immunity 1996; 5:41-52.
52. Gajewski TF, Fitch FW: Anti-proliferative effect of IFN-γ in immune regulation. I. IFN-γ inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. J Immunol 1988;140: 4245-4252.
53. Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, O'Garra AJ: IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991; 146:3444-3451.
54. Parish CR: Immune deviation: A historical perspective. Immunol Cell Biol 1996;74:449-456.
55. Liew FY, Hale C, Howard JG: Immunologic regulation of experimental cutaneous leishmaniasis. V. Characterization of effector and specific suppressor T cells. J Immunol 1982;128:1917-1922.
56. Solbach W, Forberg K, Rollinghoff M: Effect of T-lymphocyte suppression on parasite burden in Leishmania major-infected, genetically susceptible BALB/c mice. Infect Immun 1986;54:909-912.
57. Heinzel FP, Schoenhaut DS, Rerko RM, Rosser LE, Gately MK: Recombinant interleukin-12 cures mice infected with Leishmania major. J Exp Med 1993;177:1505-1509.
58. Bryceson ADM: Therapy in man; in Killick-Kendrick R, Peters W (eds): The Leishmaniases in Biology and Medicine. London, Academic Press, 1987, pp 848-907.
59. Barral-Netto M, Barrai A, Brownell CE, Skeiky YAW, Ellingsworth LR, Twardzik DR, Reed SG: Transforming growth factor-β in leishmanial infection: A parasite escape mechanism. Science 1992; 257:545-548.
60. Morris L, Troutt AB, Handman E, Kelso A: Changes in the precursor frequencies of IL-4 and IFN-γ secreting CD4+ cells correlate with resolution of lesions in murine cutaneous leishmaniasis. J Immunol 1992;149:2715-2721.
61. low CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity. J Exp Med 1994;179:589-600.
62. Mocci S, Coffman RL: Induction of a Th2 population from a polarized Leishmania-specific Th1 population by in vitro culture with IL-4. J Immunol 1995;154:3779-3787.
63. Powrie F, Menon S, Coffman RL: Interleukin-4 and interleukin-10 synergize to inhibit cell-mediated immunity in vivo. Eur J Immunol 1993;23:3043-3049.
64. Nabors GS, Farrell JP: Depletion of interleukin-4 in BALB/c mice with established Leishmania major infections increases the efficacy of antimony therapy and promotes Th1-like responses. Infect Immun 1994;62:5498-5504.
65. Nabors GS, Afonso LCC, Farrell JP, Scott P: Switch from a type 2 to a type 1 T helper cell response and cure of established Leishmania major infection in mice is induced by combined therapy with interleukin-12 and pentostam. Proc Natl Acad Sci USA 1995;92:3142-3146.
66. Nabors GS, Farrell JP: Successful chemotherapy in experimental leishmaniasis is influenced by the polarity of the T cell response before treatment. J Infect Dis 1996;173:979-986.
67. Lagrange PH, MacKaness GB, Miller TE: Influence of dose and route of antigen injection on the immunological induction of T cells. J Exp Med 1974;139:528-542.
68. Parish CR: The relationship between humoral and cell-mediated immunity. Transplant Rev 1972; 13:35-66.
69. Carvalho EM, Bacellar O, Brownell C, Regis T, Coffman RL, Reed SG: Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis. J Immunol 1994;152:5949-5956.
70. Kemp M, Hey AS, Kurtzhals JAL, Christensen CBV, Gaafar A, Mustafa MD, Kordofani AAY, Ismail A, Kharazmi A, Theander TG: Dichotomy of the human T cell response to Leishmania antigens. I. Th1-like response to Leishmania major promastigote antigens in individuals recovered from cutaneous leishmaniasis. Clin Exp Immunol 1994;96:410-415.
71. Caceres-Dittmar G, Tapia FJ, Sanchez MA, Yamamura M, Uyemura K, Modlin RL, Bloom BR, Convit J: Determination of the cytokine profile in American cutaneous leishmaniasis using the polymerase chain reaction. Clin Exp Immunol 1993;91:500-505.
72. Melby P, Andrade-Narvaez FJ, Darnell BJ, Valencia-Pacheco G, Tryon V, Palomo-Cetina A: Increased expression of proinflammatory cytokines in chronic lesions of human cutaneous leishmaniasis. Infect Immun 1994;62:837-842.
73. Zwingenberger K, Harms G, Pedrosa C, Omena S, Sandkamp B, Neifer S: Determinants of the immune response in visceral leishmaniasis: Evidence for predominance of endogenous interleukin-4 over interferon-gamma production. Clin Immunol Immunopathol 1990;57:242-249.
74. Holaday BJ, Pompeu MM, Jeronimo S, Texeira MJ, Sousa A, Vasconcelos AW, Pearson RD, Abrams JS, Locksley RM: Potential role for interleukin-10 in the immunosuppression associated with kalaazar. J Clin Invest 1993;92:2626-2632.
75. Ghalib HW, Piuvezam MR, Skeiky Y, Siddig M, Hashim FA, el-Hassan AM, Russo DM, Reed SG: Interleukin-10 production correlates with pathology in human Leishmnia donovani infections. J Clin Invest 1993;92:324-329.
76. Bogdan C, Nathan C: Modulation of macrophage function by transforming growth factor beta, interleukin-4 and interleukin-10. Ann NY Acad Sci 1993;685:713-739.
77. D'Andrea A, Ma X, Aste-Amezaga M, Paganin C, Trinchieri G: Stimulatory and inhibitory effects of IL-4 and IL-13 on the production of cytokines by human peripheral blood mononuclear cells: Priming for IL-12 and tumor necrosis factor-α production. J Exp Med 1995;181:537-546.
78. Stenger S, Thruing H, Rollinghoff M, Bogdan C: Tissue expression of inducible nitric oxide synthase is closely associated with resistance to Leishmania major. J Exp Med 1994;180:783-793.
79. 1 mice with chronic cutaneous leishmaniasis. Infect Immun 1996;64:5248-5254.
80. Boyer MH, Jaffe CL: Increased susceptibility to Leishmania torpica infection in autoimmune MRL/MpJ-lpr mice. J Parasitol 1984;70:145-146.
81. Pfeffer K, Matsuyama T, Kundig TM, Wakeham A, Kishihara K, Shahinian A, Weignmann K, Ohashi PS, Kronte M, Mak TW: Mice deficient for the 55 kD tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 1993;73:457-467.
82. Rothe J, Lesslauer W, Loetscher H, Lang Y, Koebel P, Koentgen F, Althage A, Zinkernagel R, Steinmetz M, Bluethmann H: Mice lacking the tumor necrosis receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 1993;364: 798-800.
83. Erickson SL, de Sauvage FJ, Kikly K, Carver-Moore K, Pitts-Meek S, Gillet N, Sheehan KCF, Schreiber RD, Goeddel DV, Moore MW: Decreased sensitivity to tumor-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature 1994;372:560-563.
84. Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, Lowenstein CJ, Schreiber R, Mak TW, Bloom BR: Tumor necrosis factor-α is required for the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995;2:561-572.
85. Vieira LQ, Goldschmidt M, Nashleanas M, Pfeffer K, Mak T, Scott P: Mice lacking the TNF receptor p55 fail to resolve lesions caused by infection with Leishmania major, but control parasite replication. J Immunol 1996;157:827-835.
86. Zhou T, Edwards CK, Yang P, Wang Z, Bluethmann H, Mountz JD: Greatly accelerated lymphadenopathy and autoimmune disease in lpr mice lacking tumor necrosis factor receptor. I. J Immunol 1996;156:2661-2665.
87. Sytwu H-K, Liblau RS, McDevitt HO: The role of Fas/APO-1 (CD95) and TNF in antigen-induced programmed cell death in T cell receptor transgenic mice. Immunity 1996;5:17-30.
88. Singer GG, Abbas AK: The fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1994;1:365-371.